The Use of Beta-Blockers in the Acute Phase of Myocardial Infarction

  • S. Yusuf
Part of the Acute Coronary Care Updates book series (ACCU, volume 1)


In the early hours following a coronary attack, some 30% to 50% of subjects die from ventricular fibrillation. For the survivors who reach the hospital, the amount of viable myocardium that remains is an important determinant of short and long term mortality and morbidity. Patients with large areas of infarction tend (especially if there has been previous damage) to demonstrate poor left ventricular function and to develop cardiogenic shock, late ventricular arrhythmias, or secondary ventricular fibrillation. Although coronary care units may well have considerably decreased in-hospital mortality from arrhythmias, there has been little reduction in hospital deaths from the other principal causes, such as reinfarction, heart failure, or cardiogenic shock.


Myocardial Infarction Infarct Size Cardiogenic Shock Beta Blockade Poor Left Ventricular Function 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. 1.
    Miura N, Thomas R, Ganz W, et al: Circulation 59: 1148–1157, 1979PubMedGoogle Scholar
  2. 2.
    Anderson JL, Rodier HE, Green LS: Am J Cardiol 51: 1196–2002, 1983PubMedCrossRefGoogle Scholar
  3. 3.
    Yusuf S, Lopez R, Maddison A, et al: Br Heart J 45: 271–280, 1981PubMedCrossRefGoogle Scholar
  4. 4.
    Campbell RWF, Murray A, Julian DG: Br Heart J 46: 351–357, 1981PubMedCrossRefGoogle Scholar
  5. 5.
    Yusuf S, Peto R, Lewis J, Collins R, Sleight P: Prog Cardiovasc Dis 17: 335–371, 1985CrossRefGoogle Scholar
  6. 6.
    Norris RM, Brown MA, Clark ED, et al: Lancet 2: 883–886, 1984PubMedCrossRefGoogle Scholar
  7. 6.
    Norris RM, Brown MA, Clark ED, et al: Lancet 2: 883–886, 1984PubMedCrossRefGoogle Scholar
  8. 8.
    Yusuf S, Sleight P, Rossi PRF, et al: Circulation 67 (Supp I): 32–41, 1983Google Scholar
  9. 9.
    International Study of Infarct Survival. To be presented at the AHA meeting 1985Google Scholar
  10. 10.
    Hjalmarson A, Herlitz J, Holmberg S, et al: Circulation 67 (Supp 1): 26–32, 1983Google Scholar
  11. 11.
    The MIAMI Trial Research Group: Eur Heart J 6, 1985 (in press)Google Scholar
  12. 12.
    Andersen MP, Bechsgaard P, Frederiksen J, et al: Lancet 2: 865–868, 1979PubMedCrossRefGoogle Scholar
  13. 13.
    Norris RM, Clarke ED, Sammel NL, et al: Lancet 2: 907–909, 1978PubMedCrossRefGoogle Scholar
  14. 14.
    International Collaborative Study Group: N Engl J Med 310: 9–15, 1984CrossRefGoogle Scholar
  15. 15.
    Rossi PR, Yusuf S, Ramsdale D, et al: Br Med J 286: 506–510, 1983CrossRefGoogle Scholar
  16. 16.
    Sloman G, Stannard M: Br Med J 4: 508–512, 1967CrossRefGoogle Scholar
  17. 17.
    Evemy KL, Pentecost BL: Eur J Cardiol 7: 391–398, 1978PubMedGoogle Scholar
  18. 18.
    Ryden L, Arniego R, Arnmar K, et al: N Engl J Med 308: 614–618, 1983PubMedCrossRefGoogle Scholar
  19. 19.
    Waagstein F, Hjalmarson AC: Acta Med Scand (suppl) 587: 201–211, 1975Google Scholar
  20. 20.
    Ramsdale DR, Faragher EB, Bennett DH, et al: Am Heart J 103: 459–467, 1982PubMedCrossRefGoogle Scholar
  21. 21.
    Yusuf S, Collins R, Peto R: Stat Med 3: 409–420, 1984PubMedCrossRefGoogle Scholar

Copyright information

© Martinus Nijhoff Publishing, Boston 1985

Authors and Affiliations

  • S. Yusuf
    • 1
  1. 1.Clinical Trials Branch, Division of Epidemiology and ClinicalApplications, Heart, Lung and Blood InstituteBethesdaUSA

Personalised recommendations